Preliminary Results 2009
24th July 2009
Ipso Ventures plc (AIM: IPS) (“IPSO” or the “Company”), the demand led technology commercialisation business, is pleased to announce its unaudited preliminary results for the year ended 30 April 2009.
Highlights:
- IPSO model re-engineered to focus on demand led technology commercialisation
- Value added to portfolio companies:
Therakind - external funding at 61% uplift in value
Medermica - pH measurement patent filed
Axilica - product launched. - Second Loughborough company created, Polyfect Solutions.
- Acquired Cambridge Meditech.
Simon Hunt, Chairman of IPSO, said: “This has been a defining year for IPSO, as we re-engineered our model to focus on demand led technology commercialisation. Early indicators show that this model will be highly productive and create significant opportunities. We anticipate raising further funds in due course to enable us to build on our strategy.
"Our portfolio companies are performing well and we are confident of a successful exit from one of these businesses within the next year."